Blue Trust Inc
SAGE icon

Blue Trust Inc’s Sage Therapeutics SAGE Stock Holding History

Blue Trust Inc’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2
Closed -$18 – 2666
2025
Q2 		$18 Hold
2
– – ﹤0.01% 2438
2025
Q1 		$16 Hold
2
– – ﹤0.01% 2465
2024
Q4 		$11 Sell
2
-661
-100% -$4.04K ﹤0.01% 2420
2024
Q3 		$7.2K Buy
663
+633
+2,110% +$5.79K ﹤0.01% 2305
2024
Q2 		$560 Hold
30
– – ﹤0.01% 2606
2024
Q1 		$560 Buy
30
+23
+329% +$531 ﹤0.01% 2004
2023
Q4 		$0 Sell
7
-39
-85% -$773 ﹤0.01% 2673
2023
Q3 		$2K Sell
46
-5
-10% -$144 ﹤0.01% 1843
2023
Q2 		$2K Buy
51
+4
+9% +$199 ﹤0.01% 1753
2023
Q1 		$2K Sell
47
-13
-22% -$559 ﹤0.01% 2046
2022
Q4 		$2K Sell
60
-13
-18% -$496 ﹤0.01% 1959
2022
Q3 		$2K Buy
73
+24
+49% +$928 ﹤0.01% 1824
2022
Q2 		$2K Buy
+49
New +$1.64K ﹤0.01% 1693

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Huntington National Bank
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Blue Trust Inc's SAGE Position: Q3 2025 in Review

Blue Trust Inc sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 2 shares — an estimated $18 sold.

Blue Trust Inc first reported a position in SAGE in Q2 2022 and held it in 13 quarters. The position peaked at $7.2K in Q3 2024. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Blue Trust Inc reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Blue Trust Inc sold 2 Sage Therapeutics shares in Q3 2025, an estimated $18.
  • Blue Trust Inc first reported a position in Sage Therapeutics in Q2 2022 and held it in 13 quarters.
  • Blue Trust Inc's Sage Therapeutics position peaked at $7.2K in Q3 2024.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Blue Trust Inc's 13F filing for Q3 2025, filed 16 Oct 2025.